anti-General Dinutuximab Monoclonal Antibody

Research Grade Dinutuximab

CATALOG #	REACTIVITY
AAA119955	**General**

PRODUCT SYNONYMS

Dinutuximab; Monoclonal Antibody; Research Grade Dinutuximab; 14.18; MAb-14.18; MOAB Ch14.18; CAS: 1363687-32-4; anti-Dinutuximab antibody

PRODUCT SPECIFICATIONS

Reactivity	General
Clonality	Monoclonal
Isotype	IgG1-kappa
Clone Number	Dinutuximab
Purity/Purification	>95% by SDS-PAGE; Protein A or G purified from cell culture supernatant.
Form/Format	Liquid; 0.01M PBS, pH 7.4
Concentration	4 mg/ml (varies by lot)
Host Species	Chimeric
CAS	65988-71-8
Target	Ganglioside GD2
Preparation and Storage	Store at 4 degree C short term (1-2 weeks). Store at -20 degree C for 12 months. Store at -80 degree C long term. Use a manual defrost freezer and avoid repeated freeze-thaw cycles

IMAGES



Application Data
The purity of this product is >95% as determined by SEC-HPLC.



SDS-PAGE
SDS PAGE for Dinutuximab

ADDITIONAL INFORMATION

Product Categories/Family for anti-Dinutuximab antibody	Research Biosimilar

References	Dinutuximab, PMID: 29999821 Dinutuximab, PMID: 31644006 Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial, PMID: 28549783 The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma, PMID: 30433831 Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial, PMID: 30442501

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: https://stage.aaabiotech.com/monoclonal/dinutuximab-antibody-clone-dinutuximab-elisa/119955